Filing Flows › Comparisons › AYTU vs FHTX
Aytu Biopharma vs Foghorn Therapeutics: AYTU and FHTX compared
Aytu Biopharma is the larger company: $16.1M of revenue in its latest quarter (Q4 FY26) against $16.1M for Foghorn Therapeutics (Q2 2026). Foghorn Therapeutics is growing faster (+113% against +6% a year earlier). Aytu Biopharma is more profitable, with an operating margin of -4.8% against -54.8%.
Where the money goes: AYTU and FHTX
Aytu Biopharma (AYTU) · Q4 FY26
Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%, net loss $15K, operating cash flow $4.4M. The chart follows the revenue to costs, profit and cash.
Foghorn Therapeutics (FHTX) · Q2 2026
Foghorn Therapeutics, Q2 2026: revenue $16.1M (+113% year over year), operating margin -54.8%, net loss $7.2M, operating cash flow −$17.8M. The chart follows the revenue to costs, profit and cash.
| Aytu Biopharma (AYTU) | Foghorn Therapeutics (FHTX) | |
|---|---|---|
| Latest quarter | Q4 FY26 | Q2 2026 |
| Revenue | $16.1M | $16.1M |
| Revenue growth, Y/Y | +6% | +113% |
| Operating margin | -4.8% | -54.8% |
| Net earnings | −$15K | −$7.2M |
| Net margin | -0.1% | -44.7% |
| Operating cash flow | $4.4M | −$17.8M |
| Free cash flow | $4.4M | — |
| Market value | — | $132M |
| Analysts’ mean target | — | $4.17 |
Questions
Which is bigger, Aytu Biopharma or Foghorn Therapeutics?
Aytu Biopharma is the larger company: $16.1M of revenue in its latest quarter (Q4 FY26) against $16.1M for Foghorn Therapeutics (Q2 2026).
Is Aytu Biopharma or Foghorn Therapeutics growing faster?
Foghorn Therapeutics is growing faster (+113% against +6% a year earlier).
Which is more profitable, Aytu Biopharma or Foghorn Therapeutics?
Aytu Biopharma is more profitable, with an operating margin of -4.8% against -54.8%.
More: Aytu Biopharma earnings · how Aytu Biopharma makes money · Foghorn Therapeutics earnings · how Foghorn Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Sep 22, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.